Tarek Zeidan
About Tarek Zeidan
Tarek Zeidan is the VP of Pharmaceutical Sciences with a Ph.D. in organic chemistry from Florida State University, known for his work on long-acting injectables and the LinkeRx® technology platform.
Title: VP, Pharmaceutical Sciences
Tarek Zeidan holds the position of Vice President in Pharmaceutical Sciences. His role encompasses overseeing critical aspects of pharmaceutical innovation, particularly in drug development and formulation. As a VP, he leverages his extensive background in organic chemistry and pharmaceutical research to drive advancements within the field.
Education and Expertise: Ph.D. in Organic Chemistry
Tarek Zeidan earned his Ph.D. in Organic Chemistry from Florida State University, where he studied the kinetics of enediyne cyclization and investigated photochemical cycloaddition mechanisms. He also completed a postdoctoral fellowship at Northwestern University, focusing on the dynamics of photoinduced charge separation in short DNA hairpins. Additionally, he holds a B.S. in Chemistry from the American University of Beirut.
Background: Career at Alkermes Inc.
Tarek Zeidan commenced his professional career at Alkermes Inc., where he worked on the development of long-acting injectables. He was instrumental in co-inventing the LinkeRx® technology platform, contributing to medicine delivery innovations. At Alkermes, he also oversaw technical and CMC activities for various programs, and served as the Technical Team Lead for ALKS 4230 (nemvaleukin alpha), involved in treating mucosal melanoma and platinum-resistant ovarian cancer.
Achievements: Publications and Patents
With over 50 cumulative peer-reviewed publications, patents, and presentations, Tarek Zeidan has made significant contributions to pharmaceutical sciences. His expertise has been widely recognized through his extensive scholarly output, marking him as a prominent figure in his field.
Professional Contributions: Lyndra Therapeutics
At Lyndra Therapeutics, Tarek Zeidan served as the Head of the Analytical R&D group, spearheading work on the LYNXTM technology for long-acting oral therapies. He led the analytical activities for LYN-005, focused on delivering the antipsychotic drug risperidone via a weekly-administered oral capsule. His role further emphasizes his expertise in pre-formulation, formulation development, and analytical development.